[{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug\/Device Combination for Treatment of Panic Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Xenon","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobilis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Th.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces OCD Proof Of Concept Phase 2\/3 Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces $110 Million Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.11,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Eventide Asset Management","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.19,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Provides Update on PRAX-114 IND Submission for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Provides Regulatory Update on PRAX-114 Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$91.2 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Prices Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.089999999999999997,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NYX 783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Neurocentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb\/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults with ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Threonic Acid Magnesium Salt","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Neurocentria","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Sustained Release Formulation","sponsorNew":"Neurocentria \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurocentr.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Launches a Round of Fundraising for Approximately 2.5 Million Euros","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tobacco Addiction: NFL Biosciences Collaborates with The CEA To Study the Mechanism of Action of Its Drug Candidate NFL-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ CEA","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Receives \u20ac 1.7 Million In \u00ab Avance Innovation \u00bb Funding From Bpifrance","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"9","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UBC Researchers Launch Clinical Trial Exploring CBD for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"The University of British Columbia \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"The Univer.."}]